An Immunohistochemical Study for Mammalian Target of Rapamycin Signaling Pathway Including Interacting PTEN in Prostatic Acinar Adenocarcinoma and Correlation with the Patient Clinicopathological Parameters
Abstract
Background: The activation of AKT-mTOR-PTEN pathway may promote prostate cancer progression and affects response to targeted therapies. The full extent of this activation remains to be determined. Our aim: was to assess the expression of inactive mTOR, phosphor-mTOR, phosphor-AKT and loss of PTEN in prostatic adenocarcinomas then correlate their expression with the clinicopathological parameters. Methods: The study included 166 prostatic adenocarcinoma tissues using immunohistochemistry on tissue microarrays. Statistical analysis considering markers expression and correlation with the clinicopathologic parameters was done using appropriate tests. Result: The mean age was 72.63 and 75.9% were clinically high risk. Gleason score 7 and WHO grade group 5 were the commonest (31.3% and 31.9% respectively). Most patient (73.1%) were stage T2 or higher. Expression of inactive mTOR, phospho-mTOR and phosphor-AKT was seen in 96.1%, 93.5% and 95.9% respectively. The loss of PTEN expression was noted in 55.3%. There were significant correlations between Gleason pattern 4 and the expression of inactive mTOR (p value <0.001 and 0.004 respectively) and phospho-mTOR (p value 0.003 and 0.001 respectively). Gleason score 7 was significantly correlated to inactive mTOR expression (p value <0.001). There was also significant correlation between phosphor-AKT and phospho- mTOR expression with p value 0.004. Conclusion: The immunohistochemical expression of inactive mTOR, phosphor-mTOR and phosphor-AKT and loss of PTEN was appreciated in most prostate cancer cases, suggesting that activation of this pathway occur early during prostate tumorigenesis. This may indicate that targeting mTOR pathway may have a promising therapeutic role in the management of prostatic adenocarcinoma.References
Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019 Apr;10(2):63-89
https://www.cancer.org >cancer>prostate-cancer>about>key-statistics, Key Statistics for Prostate Cancer, The American Cancer Society Medical and Editorial Team, Last Medical Review, August 2019. Cited on 10th of April, 2022
https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis. Cited on 10th of April, 2022
Gamat M, McNeel DG. Androgen deprivation and immunotherapy for the treatment of prostate cancer. Endocr Relat Cancer. 2017;24(12):T297-T310. doi:10.1530/ERC-17-0145.
Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling. Int J Mol Sci. 2020 Jun 25;21(12):4507.
Edlind MP, Hsieh AC. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian journal of andrology. 2014;16:378–386.
Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, et al. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res. 2010 Jun 1;16(11):3057-66.
Liu P, Wang Z, Wei W. Phosphorylation of AKT at the C-terminal tail triggers AKT activation. Cell Cycle. 2014;13(14):2162-4.
Sekulić A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 2000 Jul 1;60(13):3504-3513.
L. C. Cantley and B. G. Neel, “New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 8, pp. 4240–4245, 1999.
F. Vazquez and W. R. Sellers, “The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling,” Biochimica et Biophysica Acta, vol. 1470, no. 1, pp. M21–M35, 2000.
Stelloo S, Sanders J, Nevedomskaya E, de Jong J, Peters D, van Leenders GJ, et al. mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma. Oncotarget. 2016 May 31;7(22):32916-24.
Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest. 2008 Sep;118(9):3051-64.
Dai B, Kong YY, Ye DW, Ma CG, Zhou X, Yao XD. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int. 2009 Oct;104(7):1009-16.
Kweldam CF, Wildhagen MF, Steyerberg EW, Bangma CH, van der Kwast TH, van Leenders GJ. Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Mod Pathol. 2015 Mar;28(3):457-64.
Statz CM, Patterson SE, Mockus SM. mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review. Target Oncol. 2017 Feb;12(1):47-59.
Lu Q, Liu Z, Li Z, Chen J, Liao Z, Wu WR, et al. TIPE2 Overexpression Suppresses the Proliferation, Migration, and Invasion in Prostate Cancer Cells by Inhibiting PI3K/Akt Signaling Pathway. Oncol Res. 2016;24(5):305-313.
Audet-Walsh É, Vernier M, Yee T, Laflamme C, Li S, Chen Y, Giguère V. SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer. Mol Cancer Res. 2018 Sep;16(9):1396-1405.
Manin M, Baron S, Goossens K, Beaudoin C, Jean C, Veyssiere G, et al. Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem J. 2002 Sep 15;366(Pt 3):729-36.
Audet-Walsh É, Dufour CR, Yee T, Zouanat FZ, Yan M, Kalloghlian G, et al. Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer. Genes Dev. 2017 Jun 15;31(12):1228-1242.
I. Vivanco and C.L. Sawyers. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2 (2002), pp. 489-501.
Jia S, Gao X, Lee SH, Maira SM, Wu X, Stack EC, et al. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov. 2013 Jan;3(1):44-51.
Copyright (c) 2022 Somaia Ahmed Saad El-Din, Shaimaa Abdel Moety, Khalid Al Hashmi, Shadia Al Sinawi, Suaad Al-Badi, Afrah Al Rashdi, Samya Al Husani, Hajer Albadi, Asem Shalaby
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
